Clinical progress in acute myeloid leukemia

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 4, 2008, Pages 597-599

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER SURVIVAL; CYTOGENETICS; EDITORIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HLA MATCHING; HUMAN; KARYOTYPE; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING;

CYTOGENETIC ANALYSIS; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; SURVIVAL ANALYSIS;

EID: 56549096891     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.08.005     Document Type: Editorial

References (13)

1. Huisman C., Meijer E., Petersen E.J., et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biology of Blood and Marrow Transplantation 14 (2008) 181-186
2. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
3. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biology of Blood and Marrow Transplantation 14 (2008) 246-255
4. Bethge W.A., Faul C., Bornhauser M., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells, Molecules & Diseases 40 (2008) 13-19
5. Majhail N.S., Brunstein C.G., Tomblyn M., et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biology of Blood and Marrow Transplantation 14 (2008) 282-289
6. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
7. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
8. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
9. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
10. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine 352 (2005) 254-266 Erratum in: N Engl J Med. 2005; 352(7):740
11. Falini B., Nicoletti I., Martelli M.F., et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109 (2007) 874-885
12. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (2008) 2776-2784
13. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine 358 (2008) 1909-1918